Diffuse Large B-Cell Lymphoma Update
Follicular Lymphoma: Early Histological Transformation May Predict Poor Prognosis
Investigators sought to determine the impact of early histological transformation of follicular lymphoma on patient outcomes and developed a novel risk prediction tool.
A Rare Lymphoma Subtype: Diagnosis, Risk Stratification, and Management
Epstein Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified, is a rare but aggressive type of lymphoma that may be associated with adverse outcomes following chemoimmunotherapy.
DLBCL: The Dangers of Secondary Involvement of the CNS
For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life-threatening.
B Cell Malignancies: Prognostic Significance of Infections (Years) Before Diagnosis
B cell malignancies are marked by immune dysfunction and heightened infection risk. These recent findings from Danish registries suggest that the problems begin years before the diagnosis of the malignancy.
Thumbs Up: Race, Ethnicity, and DLBCL Outcomes in the VA System
Researchers recently concluded that the care received by patients treated by the Veterans Health Administration for diffuse large B-cell lymphoma met the standard of care across races and ethnicities, in contrast with previous reports.
DLBCL Survivors and Subsequent Cancer Risks
In this study, 5-year survivors of diffuse large B-cell lymphoma (DLBCL) treated with radiotherapy and/or immunochemotherapy experienced approximately 1.5 times higher rates of subsequent malignant neoplasms (SMNs) compared to the general population.
In Patients with DLBCL, Hypercalcemia Increases Morbidity and Mortality
Investigators compared outcomes of DLBCL patients hospitalized for chemotherapy with and without comorbid hypercalcemia, finding significantly increased all-cause mortality and other adverse events in those with hypercalcemia.
.jpg)
Q&A with Arushi Khurana, MBBS, of the Mayo Clinic on the Heterogeneity of DLBCL
Dr. Khurana discusses the difficulties of identifying patients with DLBCL who have poor outcomes to upfront chemoimmunotherapy.
High-grade B-cell Lymphoma with MYC and BCL2 Rearrangements: Distinct Profiles
High-grade B-cell lymphoma patients with MYC and BCL2 rearrangements (HGBL-MYC/BCL2) have a more aggressive disease course and are less likely to respond to conventional chemotherapy compared to lymphoma patients who don’t have translocations, according to these findings.
In DLBCL Patients Treated With R-CHOP, Gene Markers May Predict Poor Outcomes
Researchers identified characteristics of certain genes found in patients with DLBCL who had poor outcomes, as well as a distinct gene expression pattern also linked to poor outcomes.
Gut Microbial Dysbiosis May Affect Outcomes in Patients with DLBCL
Little is known about the influence of the gut microbiome in the development of diffuse large B-cell lymphoma (DLBCL). A new study set out to change that.
Follicular Lymphoma Diagnosis with Small-Volume Biopsy: Is It Ready for Wider Use?
In this study, small-volume biopsies for the diagnosis of follicular lymphoma, ruling out recurrence, and ruling out transformation had 100% specificity.
Genetic Subgroups of Follicular Lymphoma Can Be Distinguished by Machine Learning
Researchers recently identified 2 distinct genetic subgroups in follicular lymphoma, shedding light on the factors influencing its transformation to diffuse large B-cell lymphoma. What are the implications for precision oncology?